A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

Exclusion Criteria

• •Body weight \>= 40 kg
• •ECOG performance status of 0 to 2
• •Have clinically measurable disease
• •For US sites: Have a diagnosis of CLL/SLL that meets iwCLL, NCI Working Group Guidelines which is relapsed or refractory and requires treatment with no other approved therapies available that would be more appropriate in the investigator's judgment. a. Participants must have received at least 2 prior lines of therapy
• •For Arm A:
• •Has acute promyelocytic leukemia according to world health organization (WHO) 2016 criteria or known active central nervous system (CNS) involvement of AML/MDS, unless in specific cohort (s) per study evaluation team (SET) decision
• •Need for supplemental oxygen use to maintain adequate oxygenation
• •Have evidence of uncontrolled systemic viral, bacterial, or fungal infection. Antimicrobial prophylaxis is permitted
• •For US sites: Has acute promyelocytic leukemia according to WHO 2016 criteria or known active CNS involvement of AML/MDS
• •For Arm B:
• •Need for supplemental oxygen use to maintain adequate oxygenation
• •Have evidence of uncontrolled systemic viral, bacterial, or fungal infection requiring initiation of parenteral treatment as medical intervention
• •Developed Richter's transformation or prolymphocytic leukemia
• •Known active CNS or leptomeningeal involvement of CLL/SLL